Deficient mismatch repair as a prognostic marker in stage II colon cancer patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F19%3AN0000039" target="_blank" >RIV/00064173:_____/19:N0000039 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11140/19:10399725 RIV/00669806:_____/19:10399725 RIV/00209805:_____/19:00078312
Result on the web
<a href="https://doi.org/10.1016/j.ejso.2019.05.023" target="_blank" >https://doi.org/10.1016/j.ejso.2019.05.023</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ejso.2019.05.023" target="_blank" >10.1016/j.ejso.2019.05.023</a>
Alternative languages
Result language
angličtina
Original language name
Deficient mismatch repair as a prognostic marker in stage II colon cancer patients
Original language description
BACKGROUND: A number of reports have evaluated the relationship between deficient DNA mismatch repair (dMMR) and colorectal cancer prognosis. Unfortunately, the exact prognostic role of dMMR has not been clearly established due to contradictory results. This study aims to determine the prognostic impact of dMRR in stage II colon cancer patients only. The appropriate identification of high-risk stage II colon cancers is of paramount importance in the selection of patients who may benefit from adjuvant treatment after surgery. METHODS: Four hundred and fifty-two patients with curative resection of stage II colon cancer were included. Hospital records were used as data source, providing clinical, surgical, pathology, oncology and follow-up information for statistical analysis focusing on overall survival (OS) and time to progression (TTP). Mismatch repair status was determined by immunohistochemistry. Patient survival was followed-up for a mean of 77.35 months. RESULTS: dMMR was detected in 93 of 452 patients (20.6%). No impact on overall survival (Log-Rank, p = 0.583, 95% CI 0.76-1.67). However, the hazard ratio 0.50 for TTP was highly significant (Log-Rank, p = 0.012, 95% CI 0.28-0.87) in patients with dMMR compared with those with mismatch repair proficient tumours (pMMR). CONCLUSIONS: Patients with dMMR tumours have a lower risk for recurrence compared to those with pMMR tumours, but this finding did not correlate to better overall survival
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Surgical Oncology
ISSN
0748-7983
e-ISSN
1532-2157
Volume of the periodical
45
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
1854-1861
UT code for WoS article
000491301600016
EID of the result in the Scopus database
2-s2.0-85066955109